SCHEMBL5564481

SCHEMBL5564481

OCCOCc1ccc(-c2nn(Cc3ccccc3)c3ccccc23)o1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 10/20 0.73
CYP2D6 P10635 4/20 0.73
CYP1A2 P05177 3/20 0.73
CYP3A4 P08684 2/20 0.73
KDM4E B2RXH2 2/20 0.73
NPC1 O15118 1/20 0.73
GMNN O75496 1/20 0.73
ALDH1A1 P00352 1/20 0.73
LMNA P02545 1/20 0.73
TP53 P04637 1/20 0.73
MAPT P10636 1/20 0.73
CYP2C9 P11712 1/20 0.73
HPGD P15428 1/20 0.73
ALOX15 P16050 1/20 0.73
NFKB1 P19838 1/20 0.73
MAPK1 P28482 1/20 0.73
CYP2C19 P33261 1/20 0.73
RAB9A P51151 1/20 0.73
BLM P54132 1/20 0.73
GFER P55789 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119144 0.86 PDE5A (0.72) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL5116858 0.86 PDE5A (0.71) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL3073971 0.86 PDE5A (0.85) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL5004337 0.85 PDE5A (0.82) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL29352550 0.85 PDE5A (1.00) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL187837 0.85 PDE5A (1.00) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL4849350 0.84 PDE5A (1.00) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL3075724 0.82 PDE5A (0.69) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL5558687 0.82 PDE5A (0.50) PDE5ACYP2D6CYP1A2CYP3A4KDM4E
SCHEMBL16267521 0.82 PDE5A (0.71) PDE5ACYP2D6CYP1A2CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1842332-A Compounds, compositions and methods HIF BIO INC (US) 2006-10-04 CN claimed
EP-1646382-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO INC. (US) 2006-04-19 EP claimed
US-20050187276-A1 Compounds, compositions and methods BIZBIOTECH CO., LTD. (KR) 2005-08-25 US claimed
WO-2005030121-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO, INC. (US) 2005-04-07 WO claimed
US-7226941-B2 Compound for treating angiogenesis HIF BIO, INC. (US) 2007-06-05 US disclosed
CN-1842332-A Compounds, compositions and methods HIF BIO INC (US) 2006-10-04 CN disclosed
EP-1646382-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO INC. (US) 2006-04-19 EP disclosed
US-20050187276-A1 Compounds, compositions and methods BIZBIOTECH CO., LTD. (KR) 2005-08-25 US disclosed
WO-2005030121-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO, INC. (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187276-A1 Compounds, compositions and methods HIF1A, HIF1AN, EGLN3 PDE5A 1987/4885CYP2D6 3521/4885CYP1A2 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.